ReviewJournal of oral and maxillofacial pathology : JOMFP
Immunomodulatory effects of Triphala and its constituents in oral squamous cell carcinoma and oral precancer.
Review in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Triphala Targets the SLC7A11-GSH-GPX4 Axis to Trigger Ferroptosis in Oral Cancer: An Integrated Network Pharmacology, Molecular Docking, and Experimental Validation Study.Chemical biology & drug design · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma shows increased occurrence in those who consume tobacco products, alcohol, betel quid, and areca nut, and is also considered to occur due to genetic alteration. Though there are numerous advancements in treatment, survival remains a question with late diagnosis. Hence, there are continuous inventions of new drugs. The introduction of Ayurveda in the therapy has paved the way for the longevity of the patients affected. One such introduction is the use of Triphala. The current study aims to review the anti-oxidant, anti-proliferative, anti-microbial, and apoptotic action of Triphala and thus evaluate the anti-cancer action of Triphala. A literature search was done, in various electronic databases and the data were extracted according to the predefined criteria. Original studies of 19 reports were included in the analysis. Nineteen (six studies with Triphala combination) In vitro/In vivo studies were included in this systematic review. The included study showed that Triphala effectively modulates the immune system. The effects included were anti-oxidative, immune modulation, anti-proliferative, tumor suppression, apoptotic effect, reversal of precancerous lesion, and anti-microbial action. The analyses also showed that there is no side effect of Triphala up to the recommended dosage. Triphala, is a nourishing supplement that is well-known in Ayurveda for its capacity to restore healthy tissues and promote aging gracefully through its properties such as anti-oxidant, ant-proliferative, anti-inflammatory, cytotoxic apoptotic, and immune-modulatory properties. Hence, Triphala can be a promising drug in the prevention and treatment of oral cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.